Reneuron Regulatory News (RENE)

ReNeuron Group plc

Director/PDMR Interest in Shares and Share Options

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that the following share option grants were made yesterday under the Company's Long Term Incentive Plan (the "Plan") to directors and Persons Discharging Managerial Responsibilities (PDMRs) listed below.

The Plan allows the Company to grant tax-advantaged share options under a Company Share Option Plan (the "CSOP Plan"), as well as non-tax advantaged options. Where capacity exists for a director/PDMR to be issued share options under the CSOP Plan, these options are issued in parallel with non tax-advantaged options. The figures per individual below, where applicable, therefore comprise parallel grants of both CSOP Plan share options and non tax-advantaged share options, the terms of each grant ensuring that the exercise of one type of option reduces the number exercisable under the other type of option on a share for share basis. Individuals can therefore elect, subject to their tax status, which specific option grant (CSOP or non tax-advantaged options) they exercise.

Share options granted under the CSOP Plan are over shares up to an aggregate market value of £30,000 (measured at the date of grant) and with an exercise price of 237.5 pence per share, being the closing mid-market price of the Company's shares on 15 July 2019. Non tax-advantaged options are granted at nominal value.

The share options granted to Mr Hellebø and Mr Hunt have been awarded under the Plan in connection with the Company's remuneration policy whereby executive Directors are eligible to earn a non-cash bonus payable in the form of share options based on the achievement of certain objectives in the year to 31 March 2019. In line with the terms of the Plan and the Company's remuneration policy, these share options are exercisable from the second anniversary of the award and are not subject to performance conditions.

The share options granted to Mr Adams are exercisable from the third anniversary of the award and are subject to the achievement of the following performance conditions:

1) When the Company has signed out-licensing deal(s) for any of its technologies or programmes which, together with other financial resources, provides sufficient funding to allow the achievement of clinical proof of concept data for the CTX and hRPC programmes, one third of the options will vest.

2) When the Company's share price has doubled from the price at the date of grant, one third of the options will vest.

3) When the sixth clinical trial of a ReNeuron cell therapy completes, one third of the options will vest.

Share option grants are deemed accepted by the option holder unless expressly rejected within a period of 30 days from the date of grant.

(i) The option grants are under the non-tax advantaged scheme and (where capacity exists) the CSOP Plan (as detailed above).

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.

ENQUIRIES:

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 (Disclosure in relation to share options granted to Directors and PDMRs)